Get started
Author

Karin Burger

Observed name: K. Burger
ORCID: 0000-0001-8812-8065
Observed ORCID: 0000-0001-8812-8065
OpenAlex ID: A5083615879
Subcellular Localization of the Human Proto-oncogene Protein DEK
2001 · Ferdinand Kappes, Karin Burger, et al. · Journal of Biological Chemistry · 108
PDF
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
2024 · Elisa Zanini, Nicole Forster-Gross, et al. · Frontiers in Oncology · 10
PDF
Abstract 3789: BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity
2015 · Felix Bachmann, Karin Burger, et al. · Cancer Research · 6
Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab
2014 · Felix Bachmann, Karin Burger, et al. · Cancer Research · 5
Abstract C229: BAL27862: A novel anticancer agent which dissociates microtubules and creates a distinct cellular phenotype
2009 · Felix Bachmann, Karin Burger, et al. · Molecular Cancer Therapeutics · 5
Abstract C233: BAL27862: A unique microtubule-targeted agent with a potential for the treatment of human brain tumors
2009 · Anne Schmitt-Hoffmann, Dominique Klauer, et al. · Molecular Cancer Therapeutics · 3
42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
2022 · H.A. Lane, E. Zanini, et al. · Annals of Oncology · 2
Abstract 4419: BAL101553: A highly soluble prodrug of the potent microtubule destabilizer BAL27862
2010 · Jens Pohlmann, Felix Bachmann, et al. · Cancer Research · 2
BAL27862: A Unique Microtubule Destabilizer Active Against Chemorefractory Breast Cancers.
2009 · M. Breuleux, F. Bachmann, et al. · Cancer Research · 2
Abstract 743: Development of tumor models resistant to the novel microtubule destabilizer BAL27862 (active moiety of the prodrug BAL101553)
2011 · Felix Bachmann, Franck Danel, et al. · Cancer Research · 1
Abstract 5646: BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division
2022 · Elisa Zanini, Nicole Forster-Gross, et al. · Cancer Research
Abstract 3795: BubR1 function is required for the antiproliferative activity of the novel microtubule-targeting drug BAL27862 (active moiety of the prodrug BAL101553)
2012 · Heidi Lane, Karin Burger, et al. · Cancer Research
Works count: 12
Citation count: 144
H-index: 5
I10-index: 2
Year
Topic
Type